Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Clofarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | NT5E | P21589 | 8/20 | 0.69 |
| ▸ | CD99 | P14209 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | PNP | P00491 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clofarabine SCHEMBL12595105 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL17752021 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL4570563 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL5975001 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL12139443 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL23620882 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL15468200 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL9040 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL10026375 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL18739936 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3427743-A1 | ANTI-HEPATOMA-VIRUS AGENT | Kagoshima University (JP) | 2019-01-16 | — | — | EP | claimed |
| US-7470784-B2 | Methods for synthesizing 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine | SOUTHERN RESEARCH INSTITUTE (US) | 2008-12-30 | — | — | US | claimed |
| EP-1261350-B1 | METHODS FOR SYNTHESIZING 2-CHLORO-9-(2-DEOXY-2-FLUORO-BETA-D-ARABINOFURANOSYL)-9H-PURIN-6-AMINE | SOUTHERN RES INST (US) | 2006-07-12 | — | — | EP | claimed |
| US-20050288500-A1 | Methods for synthesizing 2-chloro-9-(2-deoxy-2-fluoro-B-D-arabinofuranosyl)-9H-purin-6-amine | SOUTHERN RESEARCH INSTITUTE (US) | 2005-12-29 | — | — | US | claimed |
| US-6949640-B2 | Method for synthesizing 2-chloro-9-(2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine | SOUTHERN RESEARCH INSTITUTE (US) | 2005-09-27 | — | — | US | claimed |
| EP-1053012-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS | ENZON PHARMACEUTICALS INC (US) | 2003-07-23 | — | — | EP | claimed |
| EP-1261350-A4 | METHODS FOR SYNTHESIZING 2-CHLORO-9-(2-DEOXY-2-FLUORO-$g(b)-D-ARABINOFURANOSYL)- i 9H /i -PURIN-6-AMINE | SOUTHERN RES INST (US) | 2003-04-16 | — | — | EP | claimed |
| US-20030023078-A1 | Method for synthesizing 2-chloro-9-(2-fluoro-beta-d-arabinofuranosyl)-9h-purin-6-amine | SOUTHERN RESEARCH INSTITUTE | 2003-01-30 | — | — | US | claimed |
| EP-1261350-A1 | METHODS FOR SYNTHESIZING 2-CHLORO-9-(2-DEOXY-2-FLUORO-$g(b)-D-ARABINOFURANOSYL)- i 9H /i -PURIN-6-AMINE | Southern Research Institute (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2001010454-A9 | PHARMACEUTICAL COMPOSITION COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTION | AVENTIS PHARM PROD INC (US) | 2002-11-07 | — | — | WO | claimed |
| EP-1143990-A3 | PHARMACEUTICAL COMPOSTIONS COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS | Aventis Pharmaceuticals Inc. (US) | 2002-03-27 | — | — | EP | claimed |
| EP-1143990-A2 | PHARMACEUTICAL COMPOSTIONS COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS | Aventis Pharmaceuticals Inc. (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2001060383-A1 | METHODS FOR SYNTHESIZING 2-CHLORO-9-(2-DEOXY-2-FLUORO-β-D-ARABINOFURANOSYL)-9H-PURIN-6-AMINE | SOUTHERN RESEARCH INSTITUTE (US) | 2001-08-23 | — | — | WO | claimed |
| WO-2001010454-A2 | PHARMACEUTICAL COMPOSITION COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTION | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2001-02-15 | — | — | WO | claimed |
| EP-1053012-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-22 | — | — | EP | claimed |
| WO-1999039732-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-08-12 | — | — | WO | claimed |
| US-5661136-A | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents | SOUTHERN RESEARCH INSTITUTE (US) | 1997-08-26 | — | — | US | claimed |
| EP-0314011-A2 | Purine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-05-03 | — | — | EP | claimed |
| US-10987372-B2 | Anti-hepatoma-virus agent | KAGOSHIMA UNIVERSITY (JP) | 2021-04-27 | — | — | US | disclosed |
| EP-0314011-A2 | Purine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987372-B2 | Anti-hepatoma-virus agent | HAVCR2, HDGF, HDGFL3 | PDE2A 4650/4885ADORA3 2205/4885PDE4D 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.